Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors pembrolizumab, atezolizumab, and cemiplimab in CSCC, followed by a focused discussion of recent cemiplimab trial data.